Clinical trial · Observational
Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome
Prevalence and Prognostic Value of Epstein Barr Virus (EBV) Infection in Patients With Radiologically Isolated Syndrome (RIS)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The clinical course of RRMS patients is variable. Among RIS-Consortium international cohorts, one third of RIS patients progressed to MS at 5 years and 52.2% at 10 years. Biomarkers predictive of MS conversion are key elements to organize personalized medical care, for both follow-up and treatment strategies. EBV seems to be an interesting candidate regarding its involvement MS pathophysiology. It can be easily assess in blood sample in contrast to others prognostic biomarkers validated in RIS : oligoclonal bands and NfL levels in cerebrospinal fluid and serum. In RIS, treatment targeting EBV could significantly modify the course of the disease. The investigators aim to make the fisrt description of the EBV epidemiology (immunoglobulin (Ig)M and IgG anti-viral capsid antigen (VCA), IgG anti Epstein-Barr nuclear antigen (EBNA)) among RIS patients and to investigate a correlation between the different antibodies' titers (IgM VCA, IgG VCA, IgG EBNA) and the course of the disease (clinical conversion or evidence of disease activity (EDA)).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epstein-Barr Virus | — | UNRESOLVED | — |
| Multiple Sclerosis | — | UNRESOLVED | — |
| Radiologically Isolated Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NO INTERVENTION | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- RIS Patient
- description
- RIS patients validated by the RIS expert group
- interventionNames
- Other: NO INTERVENTION
Primary outcomes (1)
- measure
- Comparaison of IgG EBNA status at RIS diagnostic in patients who remain RIS and those who develop MS according to their conversion delay
- timeFrame
- Retrospectively at baseline (RIS diagnosis)
- description
- IgG EBNA (negative/positive)
Secondary outcomes (6)
- measure
- Comparaison of IgM VCA EBNA status at RIS diagnostic in patients who remain RIS and those who develop MS according to their conversion delay
- timeFrame
- Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Patients with RIS confirmed by the RIS expert center of the Nice CHU; EBNA status at RIS diagnosis available Exclusion Criteria: none
References
Publications (0)
Data not yet available